These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 21940291)

  • 1. Current concerns and difficulties in the prevention of cardiovascular diseases.
    Rallidis LS; Anastasiou-Nana MI
    Hellenic J Cardiol; 2011; 52(5):437-41. PubMed ID: 21940291
    [No Abstract]   [Full Text] [Related]  

  • 2. Polish Forum for Prevention Guidelines on the so-called new cardiovascular risk factors and markers, which have a potentially significant role in the strategy for the prevention of cardiovascular diseases.
    Undas A; Podolec P; Kopeć G; Pajak A; Gasior Z; Małecki M; Pasowicz M; Rynkiewicz A; Torbicki A; Zdrojeski T; Czarnecka D; Drygas W; Godycki-Cwirko M; Kozek E; Naruszewicz M; Opala G; Stańczyk J; Sieradzki J
    Kardiol Pol; 2007 Nov; 65(11):1396-8. PubMed ID: 18303602
    [No Abstract]   [Full Text] [Related]  

  • 3. Plasma apolipoprotein-B is an important risk factor for cardiovascular disease, and its assessment should be routine clinical practice.
    Trompet S; Packard CJ; Jukema JW
    Curr Opin Lipidol; 2018 Feb; 29(1):51-52. PubMed ID: 29298274
    [No Abstract]   [Full Text] [Related]  

  • 4. Inflammatory markers for risk stratification in primary prevention of cardiovascular disease: time for a 'multimarker' approach?
    Ikonomidis I; Lekakis J; Kremastinos DT
    Thromb Haemost; 2006 Mar; 95(3):397-8. PubMed ID: 16525564
    [No Abstract]   [Full Text] [Related]  

  • 5. Coronary artery calcium scanning should be used for primary prevention: pros and cons.
    Nasir K; Shaw LJ; Budoff MJ; Ridker PM; Peña JM
    JACC Cardiovasc Imaging; 2012 Jan; 5(1):111-8. PubMed ID: 22239900
    [No Abstract]   [Full Text] [Related]  

  • 6. Criteria for considering people at risk for cardiovascular disease prevention; guidelines of the Joint British Societies of cardiovascular disease in clinical practice.
    Sargazi M; Neithercut D
    Ann Clin Biochem; 2007 Mar; 44(Pt 2):196. PubMed ID: 17362589
    [No Abstract]   [Full Text] [Related]  

  • 7. Progress in prevention: should we screen for risk factors or disease? A current debate in the prevention of cardiovascular events.
    Dennison CR; Hughes S
    J Cardiovasc Nurs; 2009; 24(1):18-20. PubMed ID: 19114796
    [No Abstract]   [Full Text] [Related]  

  • 8. [New recommendations of 2016 European Guidelines on cardiovascular disease prevention].
    Escobar C; Divisón JA
    Semergen; 2017; 43(4):330-331. PubMed ID: 27507013
    [No Abstract]   [Full Text] [Related]  

  • 9. European guidelines on cardiovascular disease prevention in clinical practice: past, present, and future: a need for joint forces.
    Cífková R; Mancia G; Kjeldsen SE; Laurent S
    J Hypertens; 2008 Feb; 26(2):157-60. PubMed ID: 18192823
    [No Abstract]   [Full Text] [Related]  

  • 10. Statins in the elderly: what evidence of their benefit in prevention?
    Steg PG; Tissot CM
    Arch Cardiovasc Dis; 2010 Feb; 103(2):61-5. PubMed ID: 20226424
    [No Abstract]   [Full Text] [Related]  

  • 11. [HDL in the guidelines of cardiovascular diseases prevention].
    Rynkiewicz A; Bellwon J
    Kardiol Pol; 2005 Jun; 62 Suppl 2():II17-24. PubMed ID: 19813330
    [No Abstract]   [Full Text] [Related]  

  • 12. Secondary cardiovascular risk prevention--we can do better.
    Brekke M; Gjelsvik B
    Lancet; 2009 Mar; 373(9667):873-5. PubMed ID: 19286069
    [No Abstract]   [Full Text] [Related]  

  • 13. The current role of ACE-inhibitors for secondary prevention in cardiovascular disease; from pathogenesis to clinical practice.
    Voors AA; van Veldhuisen DJ; van Gilst WH
    Cardiovasc Drugs Ther; 2006 Feb; 20(1):69-73. PubMed ID: 16619108
    [No Abstract]   [Full Text] [Related]  

  • 14. AHA examines cardiovascular problems in diabetes. American Heart Association.
    Morey SS
    Am Fam Physician; 2000 Jan; 61(2):561, 563-4, 567. PubMed ID: 10670513
    [No Abstract]   [Full Text] [Related]  

  • 15. What role does HDL cholesterol have in CVD and what is the most effective way to increase it?
    Marcason W
    J Am Diet Assoc; 2011 Aug; 111(8):1266. PubMed ID: 21802575
    [No Abstract]   [Full Text] [Related]  

  • 16. Introduction: Apolipoproteins and guidelines for prevention of cardiovascular disease.
    Faergeman O
    J Intern Med; 2006 May; 259(5):434-6. PubMed ID: 16629848
    [No Abstract]   [Full Text] [Related]  

  • 17. Treat-to-target versus dose-adapted statin treatment of cholesterol to reduce cardiovascular risk.
    Müller-Wieland D; Assmann G; Carmena R; Davignon J; von Eckardstein A; Farinaro E; Greten H; Olsson AG; Riesen WF; Shlyakhto E
    Eur J Prev Cardiol; 2016 Feb; 23(3):275-81. PubMed ID: 25595550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular disease in patients with inflammatory bowel disease: An issue in no guidelines land.
    Zuin M; Rigatelli G; Del Favero G; Andreotti AN; Picariello C; Zuliani G; Carraro M; Galasso MP; Roncon L
    Int J Cardiol; 2016 Nov; 222():984-985. PubMed ID: 27526375
    [No Abstract]   [Full Text] [Related]  

  • 19. Time to improve statin prescription guidelines in low-risk patients?
    Balder JW; de Vries JK; Mulder DJ; Kamphuisen PW
    Eur J Prev Cardiol; 2017 Jul; 24(10):1064-1070. PubMed ID: 28429651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Psychosocial risk factors in therapeutic guidelines for cardiovascular risk].
    Orth-Gomér K
    Lakartidningen; 2004 Dec; 101(49):4053. PubMed ID: 15633352
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.